Skip to main content
. 2018 Oct 15;9:2323. doi: 10.3389/fimmu.2018.02323

Figure 4.

Figure 4

Incomplete germinal center disruption after alemtuzumab treatment in the lymph node and spleen. (A) Significantly higher frequency of CD3 T cells were found in the lymph nodes compared to other immune compartments at POD 5 and POD 14 (Gray area = non-depleted control, Red line = alemtuzumab treated). (B) Immunohistochemistry demonstrated cell components of germinal center. T, B, Ki67 and PNA staining confirmed germinal center (GC) response at 24 h after alemtuzumab treatment.